EZH2 and hepatocellular carcinoma: EZH2 recruited DNMT3A to the promoter of ULBP1, increasing DNA methylation and thus down-regulating the expression of NKG2D ligands to resist NK-cell-mediated cytotoxicity in hepatoma cells.